arrow
I

Irene Marini

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
H指数:13
被引数:874

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

基线血清癌胚抗原(CEA)是接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的独立预后生物标志物

2026-09-110
OAAI
Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)

术后VABB腔内靶向亲和素预靶向[90Y]Y-DOTA-生物素在非可触及乳腺癌中的应用:一项I期剂量递增研究(ARTHE)

Cancers
IF4.4
2026-08-280
OA
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024-08-290
OAAI
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
2020-05-2047
PREAI